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Supplementary Method 1. Medication lists. 
 
1. Sleep medications: oxazepam, meprobamate, medazepam, bromazepam, 
lorazepam, clobazam, chlormezanone, temazepam, nitrazepam, lormetazepam, 
diazepam, zopiclone, triclofos, methyprylone, prazepam, triazolam, ketazolam, 
dichloralphenazone, clomethiazole, zaleplon, butobarbital. 
 
2. Antidepressants: amitriptyline, citalopram, fluoxetine, sertraline, venlafaxine, 
dosulepin, paroxetine, mirtazapine, escitalopram, trazodone, prozac, seroxat, cipralex, 
duloxetine, lofepramine, clomipramine, nortriptyline, imipramine, dothiepin, cipramil, 
amitriptyline, prothiaden, trimipramine, lustral, reboxetine, zispin, cymbalta, anafranil, 
doxepin, moclobemide, phenelzine, fluvoxamine, yentreve, triptafen, surmontil, 
tranylcypromine, allegron, edronax, molipaxin, mianserin, nardil, faverin, nefazodone, 
amitriptyline+chlordiazepoxide, isocarboxazid, manerix, maoi, sinequan, 
tranylcypromine+trifluoperazine, ludiomil, norval, tryptizol, and fluphenazine 
hydrochloride+nortriptyline. 
 
3. Antipsychotics: prochlorperazine, olanzapine, quetiapine, risperidone, 
chlorpromazine, trifluoperazine, amisulpride, sulpiride, seroquel, haloperidol, 
aripiprazole, stelazine, depixol, flupentixol, clozapine, promazine, risperdal, modecate, 
fluanxol, flupenthixol, zyprexa, zuclopenthixol, clopixol, largactil, abilify, fluphenazine, 
haldol, serenace, clozaril, cpz, perphenazine, levomepromazine, pericyazine, dolmatil, 
fentazin, fluphenazine, benperidol, pimozide, zaponex, denzapine, neulactil, 
thioridazine, dozic, fluspirilene, panadeine, and sertindole.  
 
4. Anxiolytics: zopiclone, diazepam, temazepam, zolpidem, nitrazepam, lorazepam, 
hydroxyzine, zimovane, phenergan, promethazine, buspirone, atarax, oxazepam, 
loprazolam, chlordiazepoxide, lormetazepam, ucerax, stilnoct, diazepam, buspar, 
alprazolam, librium, xanax, meprate, dalmane, clomethiazole, meprobamate, welldorm, 
amitriptyline+chlordiazepoxide, flurazepam, heminevrin, medazepam, neulactil, 
sinequan, almazine, atensine, carisoma, chloractil, chloral, dichloralphenazone, 
dormonoct, methyprylone, mogadon, rohypnol, tryptizol. 
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Supplementary Method 2. Criteria for identifying participants with psychiatric disorders 
(https://www.biorxiv.org/content/biorxiv/early/2017/08/01/168732.full.pdf). 
 
Cases of psychiatric disorder was determined using any of the following definitions 
(derived from Howard et al.):  
 
1) ICD-10 codes for major depressive disorder (F32, F33), bipolar disorder (F30, 
F31), schizophrenia (F20-F29), autism (F84.0, F84.3, F84.5), intellectual 
disability (F70.0, F70.1, F70.9), anxiety disorder (F40 - F43), multiple personality 
disorder (F44.8), or mood disorder (F30 - F39).  
 
2) Self-reported antidepressant, antipsychotic, or anxiolytic use at nurse-led 
interview. 
 
3) Self-reported depression, major depressive disorder, bipolar disorder, or 
schizophrenia at nurse-led interview. 
 
4) “Broad depression”: responded yes to the question “Have you ever seen a 
general practitioner (GP) for nerves, anxiety, tension or depression?” and yes to 
either, “have you ever had a time when you were feeling depressed or down for 
at least a whole week,” or, “Have you ever had a time when you were 
uninterested in things or unable to enjoy the things you used to for at least a 
whole week?” lasting for more than 1 week. 
 
5) Questionnaire-assessed bipolar disorder (Smith algorithm1): responded yes to 
the question, “Have you ever had a period of time lasting at least two days when 
you were feeling so good, "high", excited or "hyper" that other people thought you 
were not your normal self or you were so "hyper" that you got into trouble?” or 
“Have you ever had a period of time lasting at least two days when you were so 
irritable that you found yourself shouting at people or starting fights or 





1 Smith, D.J. et al. Prevalence and characteristics of probable major depression and bipolar disorder 
within UK Biobank: cross-sectional study of 172,751 participants. PLoS ONE 8,e75362 (2013). 
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Supplementary Figure 1. Q-Q plots for genome-wide association of sleep traits. Q-
Q plots show the expected verses observed P values from our association analysis. 
Lambda inflation values (λ) were computed using GenABEL in R. 
 
a. Sleep duration (λ = 1.432)   b. Sleep duration (add’ exclusions) (λ = 1.344) 
 
c. Sleep duration (men) (λ = 1.177)  d. Sleep duration (women) (λ = 1.229)  
 
e. Short sleep (λ = 1.262)   f. Long sleep (λ = 1.160) 
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Supplementary Figure 2. Manhattan plot for genome-wide association analysis of 
sleep duration with additional exclusions (n =326,224). Manhattan plot shows the -
log10 P values (y-axis) for all genotyped and imputed SNPs passing quality control, plotted 
by chromosome (x-axis). Blue peaks represent genome-wide significant loci. Novel loci 






Supplementary Figure 3. Manhattan plots for genome-wide association analysis of 
sex-stratified sleep duration. Manhattan plots a and b show the -log10 P values (y-axis) 
for all genotyped and imputed SNPs passing quality control in each GWAS, plotted by 
chromosome (x-axis). Blue peaks represent genome-wide significant loci. Horizontal red 





        
b. Women 
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Supplementary Figure 4. Comparison of short and long sleep GWAS effect estimates 
of 8 long sleep signals. Odds Ratio (OR) reflects the odds of having short/long sleep per 
each additional effect allele, and error bars indicate 95% CI. Abbreviations: OR=odds 
ratio; CI=confidence interval. Association effect estimates in this figure can be found in 





Supplementary Figure 5. Manhattan plots for genome-wide association meta-
analyses. Manhattan plots show the -log10 P values (y-axis) for all genotyped and 
imputed SNPs passing quality control in each GWAS, plotted by chromosome (x-axis). 
Blue peaks represent additional novel genome-wide significant loci unraveled in meta-
analysis. Horizontal red line denotes genome-wide significance (5 x 10-8). SNPs with high 
heterogeneity (I2 >=90) were excluded. Association effect estimates in this figure can be 
found in tabular form in Supplementary Data 7.	
 
a. UK Biobank + CHARGE (adult) (n =493,298) 
 
b. UK Biobank + EAGLE (childhood/adolescent) (n =456,672) 
 
c. UK Biobank + CHARGE + EAGLE (n =503,852) 
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Supplementary Figure 6. Association of sleep loci (7 sleep duration loci, a–g; 5 short 
sleep loci, h–l; 3 long sleep loci, m–o) with brain imagining phenotypes in the UK Biobank 
(images from http://big.stats.ox.ac.uk/). 
 
a. Sleep duration (rs7556815) – PAX8 
 
b. Sleep duration (rs13109404) – BANK1 
 
 
c. Sleep duration (rs330088) – PPP1R3B 
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d. Sleep duration (rs11602180) – PTPRJ 
 
 




f. Sleep duration (rs174560) – FADS1/FADS2 
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g. Sleep duration (rs12611523) – SPOPL 
 
 
h. Short sleep (rs2863957) – PAX8 
 
 
i. Short sleep (rs13107325) – SLC39A8 
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j. Short sleep (rs2820313) – LMOD1 
 
 
k. Short sleep (rs2186122) – PDE4B 
 
 




m. Long sleep (rs6737318) – PAX8 
 
 
n. Long sleep (rs7534398) – CAMTA1 
 
 
o. Long sleep (rs10899257) – GUCY2E 
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Supplementary Figure 7. Causal relationship of sleep duration with BMI (GIANT: a,b) or 
type 2 diabetes (DIAGRAM: c,d). Association between single nucleotide polymorphisms 
(SNP) associated with sleep duration and outcomes (a,c), and lines identify the slopes of 
the five methods tested. Forest plot shows the estimate of the effect of genetically 
increased sleep duration (in minutes) on outcomes (kg/m2 or log OR; b,d). Forest plots 
show each SNP with the 95% confidence interval (gray line segment; error bars) of the 
estimate and the Inverse Variance MR, MR-Egger, and Weighted Median MR results in 






Supplementary Table 1. Descriptive table of UK Biobank participants of European ancestry (n =446,118) included in 
sleep duration genome-wide association study. 
      
  Sleep Duration   
Characteristic All  (N =446,118) 
Short (7h) 
(N =106,192) 






Sex (female), % 54.1 53.1 54.2 56.1 < 2.2e-16 
Age, y 57.3 (8.0) 57.2 (7.8) 57.1 (8.1) 59.3 (7.9) < 2.2e-16 
Sleep duration, hours 7.2 (1.1) 5.7 (0.5) 7.4 (0.5) 9.3 (0.7) N/A 
BMI, kg/m2 27.4 (4.7) 27.9 (5.1) 27.1 (4.6) 28.1 (5.1) < 2.2e-16 
Coffee intake, cups/day 2.2 (2.0) 2.3 (2.2) 2.1 (1.9) 2.1 (2.1) < 2.2e-16 
Tea intake, cups/day 3.5 (2.7) 3.6 (2.9) 3.5 (2.6) 3.7 (2.9) 5.36E-05 
Alcohol intake, g/day 2.9 (1.5) 3.0 (1.5) 2.8 (1.4) 3.0 (1.6) < 2.2e-16 
Townsend Deprivation Index -2.3 (-3.1 to 0.2) -2.0 (-3.5 to 0.8) -2.4 (-3.8 to -0.1) -2.1 (-3.6 to 0.6) < 2.2e-16 
Sleep apnea, % 1.2 1.7 1.0 1.7 < 2.2e-16 
Insomnia symptoms, % 28.0 51.0 20.7 21.2 < 2.2e-16 
Physical activity, MET-h/week 28.3 (12.9 to 58.2) 28.3 (12.2 to 61.7) 28.4 (13.2 to 57.1) 26.6 (11.6 to 56.0) 1.98E-03 
Nap during day, %         < 2.2e-16 
Never/Rarely 56.7 58.8 58.2 35.9   
Sometimes 38.1 36.9 37.4 47.5   
Always 5.2 4.2 4.3 16.5   
Smoking Status, %         < 2.2e-16 
Never/Rarely 53.9 51.4 55.3 50.0   
Current 10.3 12.5 9.3 11.6   
Former 35.5 35.7 35.1 38.0   
Employment Status, %         < 2.2e-16 
Employed 57.3 60.0 59.1 33.2   
Retired 34.3 30.3 33.8 52.1   
Other 8.4 9.7 7.1 14.3   
Menopause status, % yes 33.2 34.4 32.5 35.4 3.68E-03 
Chronic and psychiatric disorders, % 16.1 18.1 14.3 24.9 < 2.2e-16 
Antidepressant medication, % 7.1 7.6 5.9 15.8 < 2.2e-16 
Antipsychotic medication, % 0.5 0.5 0.4 1.8 < 2.2e-16 
Shift Worker, %         < 2.2e-16 
Never/Rarely 47.9 47.4 50.4 26.8   
Sometimes 4.1 5.1 3.9 2.5   
Usually 1.1 1.4 1.0 0.8   
Always 4.2 6.0 3.6 3.1   
      
Mean ± standard deviation or N(%) or Median [IQR]. P-values derived from chi-squared or anova test. A greater Townsend 
index score implies a greater degree of deprivation. 
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Supplementary Table 2. Conditional analyses for sleep duration in the UK Biobank participants of European ancestry 
using the approximate conditional and joint association method implemented in GCTA unravels additional independent 
signals. 
             













(E/A) EAF Beta (min) SE (min) P Value Beta (min) SE (min) P Value 
rs75539574 2:58871658 
VRK2,  
LINC01122 rs2717076 2:58061127 T/C 0.627 1.105 0.140 3.10E-15 1.038 0.141 1.57E-13 
rs365663 5:1428883 SLC6A3 rs7718889 5:7200526 A/T 0.630 0.768 0.141 5.60E-08 0.776 0.141 3.55E-08 
rs7115226 11:113408518 DRD2 rs2075654 11:113289066 T/C 0.158 1.092 0.186 6.40E-09 1.020 0.187 4.63E-08 
rs1991556 17:44083402 
MAPT, STH,  
KANSL1, 
LOC644157, 
LOC644172 rs9895274 17:45539117 C/T 0.510 0.801 0.136 4.70E-09 0.790 0.136 6.43E-09 
             
Abbreviations: Chr=chromosome, E/A=effect/alternative, position=base pair coordinate hg19, SNP=single 




Supplementary Table 3. Novel loci identified for sleep duration from genome-wide association study (P <5x10-8) for 
sleep duration with additional exclusions for shift work and prevalent chronic diseases and psychiatric disorders in 
participants of European ancestry from UK Biobank (n =326,224) and corresponding results from the sleep duration 
GWAS without these exclusions. 
            








(E/A) EAF Info Beta (min) SE (min) P Value Beta (min) SE (min) P Value 
rs226063 1:44803346 ERI3, DMAP1 C/T 0.298 1.00 0.929 0.162 1.10E-08 0.731 0.148 9.50E-07 
rs57316292 3:61792378 PTPRG A/G 0.903 0.99 1.400 0.250 1.40E-08 1.159 0.230 3.40E-07 
rs41845 7:69025267 AUTS2 T/G 0.347 1.00 0.876 0.155 1.50E-08 0.725 0.143 4.20E-07 













G/A 0.833 1.00 1.088 0.198 4.10E-08 0.915 0.182 4.10E-07 
            
Genetic association analysis was performed in related subjects of European ancestry using BOLT-LMM linear mixed 
models and an additive genetic model adjusted for age, sex, 10 principal components of ancestry, genotyping array and 
genetic correlation matrix [jl2]. Bold denotes genome-wide significant signals (p<5x10-8). Genes indicate all genes within 
the locus of interest; bold genes indicate nearest gene. Beta (SE) estimates are per each additional effect allele. 
Abbreviations: Chr=chromosome, E/A=effect/alternative alleles, EAF=effect allele frequency, Info=imputation quality 




Supplementary Table 4. Genetic correlations between sex-stratified sleep duration GWAS models. Genetic correlation 
between reported sleep traits are estimated by LDSC. 



















































Supplementary Table 5. Genome-wide association signals (P <5x10-8) for long sleep in participants of European 
ancestry from UK Biobank (n =34,184 cases/305,742 controls) and corresponding results from short sleep (n =106,192 
cases/305,742 controls) and sleep duration (n =446,118) GWAS. 
             
		 		 		 		 		 		





Nearest gene(s) Alleles  (E/A) EAF Info OR [95% CI] P Value OR [95% CI] P Value Beta SE P Value 
rs6737318 2:114083120 PAX8, LOC100130100 G/A 0.222 0.99 1.079 [1.056-1.103] 3.40E-13 0.948 [0.934-0.961] 4.70E-18 2.442 0.164 1.60E-49 
rs75458655 11:118115331 MPZL2, JAML, MPZL3 T/C 0.023 1.00 1.203 [1.136-1.275] 5.40E-12 0.967 [0.93-1.006] 2.10E-01 2.064 0.455 5.00E-06 
rs17688916 17:43778680 CRHR1, KIAA1267, LOC644246 T/A 0.796 0.96467 1.074 [1.048-1.1] 1.10E-11 1.003 [0.988-1.018] 8.90E-01 0.903 0.172 1.30E-07 
rs17817288 16:53807764 FTO, RPGRIP1L A/G 0.518 1.00 1.04 [1.021-1.059] 8.90E-09 0.992 [0.981-1.004] 9.50E-02 0.829 0.136 1.20E-09 
rs549961083 5:58184093 RAB3C, PDE4D T/C 0.001 0.868466 1.705 [1.357-2.143] 9.60E-09 1.211 [1.025-1.43] 4.80E-04 49.74 8.16 5.00E-01 
rs3751046 11:122828342 BSX, C11orf63 G/A 0.147 0.99 1.072 [1.044-1.099] 2.00E-08 0.975 [0.96-0.992] 2.50E-03 1.165 0.192 1.10E-09 
rs7534398 1:7767464 CAMTA1, VAMP3, PER3, UTS A/T 0.201 0.99 1.048 [1.024-1.072] 2.10E-08 0.994 [0.98-1.009] 3.50E-01 0.738 0.170 1.20E-05 
rs10899257 11:76415209 GUCY2E, LRRC32, TSKU A/G 0.144 1.00 1.07 [1.043-1.098] 4.60E-08 1.011 [0.995-1.028] 1.80E-01 0.419 0.193 2.70E-02 
             
Genetic association analysis was performed in related subjects of European ancestry using BOLT-LMM linear mixed 
models and an additive genetic model adjusted for age, sex, 10 principal components of ancestry, genotyping array and 
genetic correlation matrix [jl2]. OR [95% CI] estimates for short/long sleep are from adjusted PLINK logistic regression 
analyses. OR [95% CI] or Beta (SE) estimates are per each additional effect allele. Bold denotes genome-wide significant 
signals (p<5x10-8). Genes indicate all genes within the locus of interest; bold genes indicate nearest gene. 
Abbreviations: Chr=chromosome, E/A=effect/alternative alleles, EAF=effect allele frequency, Info=imputation quality 




Supplementary Table 6. Sensitivity analysis for genome-wide significant long sleep loci (P <5x10-8) in participants of 
European ancestry from UK Biobank (n =34,184 cases/305,742 controls), adjusting for known risk factors. 
          
		 		





OR [95% CI] P Value OR [95% CI] P Value OR [95% CI] P Value OR [95% CI] P Value 
rs6737318 2:114083120 1.079 [1.056-1.103] 3.40E-13 1.08 [1.056-1.104] 2.30E-13 1.079 [1.055-1.103] 3.80E-13 1.082 [1.058-1.106] 1.10E-13 
rs75458655 11:118115331 1.203 [1.136-1.275] 5.40E-12 1.204 [1.136-1.276] 5.30E-12 1.203 [1.135-1.274] 6.80E-12 1.201 [1.132-1.274] 3.10E-12 
rs17688916 17:43778680 1.074 [1.048-1.1] 1.10E-11 1.074 [1.048-1.1] 9.50E-12 1.074 [1.048-1.1] 9.80E-12 1.059 [1.033-1.085] 1.50E-07 
rs17817288 16:53807764 1.04 [1.021-1.059] 8.90E-09 1.053 [1.033-1.072] 4.90E-13 1.039 [1.02-1.059] 1.50E-08 1.047 [1.028-1.067] 7.10E-08 
rs549961083 5:58184093 1.705 [1.357-2.143] 9.60E-09 1.708 [1.358-2.148] 8.30E-09 1.707 [1.358-2.145] 8.80E-09 1.78 [1.409-2.248] 7.60E-09 
rs3751046 11:122828342 1.072 [1.044-1.099] 2.00E-08 1.073 [1.046-1.101] 1.10E-08 1.071 [1.044-1.099] 2.60E-08 1.074 [1.046-1.103] 2.30E-08 
rs7534398 1:7767464 1.048 [1.024-1.072] 2.10E-08 1.047 [1.023-1.071] 4.20E-08 1.048 [1.024-1.072] 2.30E-08 1.05 [1.026-1.075] 1.10E-08 
rs10899257 11:76415209 1.07 [1.043-1.098] 4.60E-08 1.071 [1.044-1.099] 3.40E-08 1.07 [1.043-1.098] 4.30E-08 1.072 [1.044-1.1] 3.00E-08 
          
Genetic association analysis was performed in related subjects of European ancestry using BOLT-LMM linear mixed 
models and an additive genetic model adjusted for age, sex, 10 principal components of ancestry, genotyping array and 
genetic correlation matrix [jl2] as baseline and additional covariates as indicated for each analysis. OR [95% CI] estimates 
for short/long sleep are from adjusted PLINK logistic regression analyses. Additional lifestyle and clinical adjustments 
included BMI, day naps, Townsend index, smoking, alcohol intake, menopause status, employment status, and sleep 
apnea in addition to baseline adjustments. For further details on sensitivity variables, see methods.  All analyses 
performed in subjects with non-missing covariates. OR [95% CI] estimates are per each additional effect allele. 





Supplementary Table 7. Low genetic correlation between adult (UK Biobank and CHARGE) and childhood/adolescent 
(EAGLE) genome-wide association studies for sleep duration. Genetic correlation between reported sleep traits are 
measured by LDSC. 
            
Study 1 Study 2 rg SE z P value h2_obs h2_obs_se h2_int h2_int_se gcov_int gcov_int_se 
UK Biobank CHARGE 1.000 0.123 8.152 3.59E-16 0.037 0.009 1.011 0.006 0.000 0.005 
UK Biobank EAGLE 0.098 0.076 1.293 0.20 0.132 0.044 0.984 0.007 0.003 0.005 




Supplementary Table 8. Descriptive table of UK Biobank participants of European ancestry who had completed up to 7 
days of wrist-worn accelerometry (n =85,499). 
     
  Sleep Duration 










Sex (female), % 56.2 (49.6) 44.1 (49.7) 58.5 (49.3) 59.9 (49.0) 
Age, y 62.5 (7.8) 61.8 (8.0) 62.5 (7.8) 64.2 (7.4) 
BMI, kg/m2 26.7 (4.5) 27.5 (4.9) 26.5 (4.4) 26.5 (4.5) 
Sleep duration, hours 7.30 (0.86) 5.93 (0.56) 7.45 (0.51) 8.85 (0.33) 
Sleep duration standard deviation, hours 0.93 (0.57) 1.30 (0.85) 0.86 (0.47) 0.83 (.42) 
Sleep efficiency, % 76.18 (7.18) 69.13 (9.05) 77.17 (5.84) 81.84 (4.01) 
Number of sleep bouts, n 17.25 (3.59) 16.37 (3.81) 17.38 (3.51) 17.89 (3.57) 
Midpoint of 5-hour daily period of minimum activity (L5 
timing), HH:MM 3:19 (1:06) 3:22 (1:16) 3:19 (1:01) 3:19 (1:06) 
Midpoint of 10-hour daily period of maximum activity 
(M10 timing), HH:MM 13:41 (1:13) 13:43 (1:31) 13:41 (1:09) 13:50 (1:05) 
Daytime Inactivity Duration, hours 0.97 (0.68) 0.82 (0.60) 0.94 (0.63) 1.63 (0.95) 
Sleep Midpoint, HH:MM 2:59 (0:45) 3:01 (1.07) 3:00 (0:51) 2:49 (0:56) 
     




Supplementary Table 9. MAGMA pathway-based enrichment analysis for sleep traits based on MAGMA gene-sets. 
Top 10 of 10,891 pathways are shown. Significant pathways with P <4.59x10-06 for 10,891 tested pathways are bolded. 
        
Trait Gene Set N genes Beta Beta STD SE P Value Pbon 
Sleep Duration GO_bp:go_striatum_development 15 1.55 0.0443 0.307 2.35E-07 0.0026 
  GO_bp:go_mechanosensory_behavior 12 1.54 0.0393 0.313 4.81E-07 0.0052 
  GO_mf:go_dopamine_binding 10 1.61 0.0376 0.334 7.48E-07 0.0081 
  GO_bp:go_subpallium_development 21 1.14 0.0387 0.257 4.41E-06 0.048 
  GO_bp:go_synaptic_signaling 404 0.221 0.0325 0.0539 2.08E-05 0.23 
  Curated_gene_sets:ivanova_hematopoiesis_early_progenitor 507 0.186 0.0305 0.0468 3.54E-05 0.39 
  GO_bp:go_response_to_auditory_stimulus 23 0.936 0.0332 0.239 4.61E-05 0.50 
  GO_bp:go_adenylate_cyclase_activating_g_protein_coupled_receptor_signaling_pathway 71 0.491 0.0305 0.127 5.90E-05 0.64 
  GO_cc:go_somatodendritic_compartment 621 0.169 0.0305 0.0441 6.49E-05 0.71 
  GO_cc:go_neuron_projection 900 0.141 0.0305 0.0369 6.66E-05 0.72 
Short Sleep Curated_gene_sets:ikeda_mir1_targets_dn 7 1.6 0.0313 0.393 2.34E-05 0.25 
  Curated_gene_sets:benporath_oct4_targets 275 0.235 0.0286 0.0607 5.30E-05 0.58 
  GO_bp:go_regulation_of_potassium_ion_transport 81 0.443 0.0294 0.114 5.38E-05 0.59 
  Curated_gene_sets:kegg_glycolysis_gluconeogenesis 57 0.0421 0.00235 0.133 0.37544 1 
  Curated_gene_sets:kegg_citrate_cycle_tca_cycle 29 0.255 0.0102 0.176 0.07381 1 
  Curated_gene_sets:kegg_pentose_phosphate_pathway 23 0.0573 0.00203 0.188 0.38029 1 
  Curated_gene_sets:kegg_pentose_and_glucuronate_interconversions 29 0.198 0.00789 0.238 0.20214 1 
  Curated_gene_sets:kegg_fructose_and_mannose_metabolism 32 -0.173 -0.00723 0.163 0.85546 1 
  Curated_gene_sets:kegg_galactose_metabolism 26 0.116 0.00435 0.193 0.27453 1 
  Curated_gene_sets:kegg_ascorbate_and_aldarate_metabolism 26 -0.288 -0.0108 0.267 0.85941 1 
Long Sleep GO_bp:go_catecholamine_metabolic_process 36 0.69 0.0306 0.146 1.20E-06 0.013 
  GO_bp:go_catechol_containing_compound_metabolic_process 36 0.69 0.0306 0.146 1.20E-06 0.013 
  GO_bp:go_catecholamine_biosynthetic_process 17 0.92 0.028 0.226 2.30E-05 0.25 
  GO_bp:go_catechol_containing_compound_biosynthetic_process 17 0.92 0.028 0.226 2.30E-05 0.25 
  GO_bp:go_dopamine_metabolic_process 20 0.773 0.0255 0.191 2.61E-05 0.28 
  GO_bp:go_phenol_containing_compound_biosynthetic_process 31 0.641 0.0263 0.165 5.10E-05 0.56 
  Curated_gene_sets:reactome_microrna_mirna_biogenesis 22 0.788 0.0273 0.206 6.50E-05 0.71 
  Curated_gene_sets:kurokawa_liver_cancer_chemotherapy_dn 39 0.508 0.0234 0.136 8.87E-05 0.97 
  Curated_gene_sets:kegg_glycolysis_gluconeogenesis 57 0.00534 0.000298 0.122 0.48255 1 




Supplementary Table 10. Pascal pathway-based enrichment test for sleep traits using Pascal (gene-set enrichment 
analysis using 1,077 pathways from KEGG, REACTOME, BIOCARTA databases). Top 10 of 1,077 pathways are 
shown. Significant pathways with P <4.64x10-05 for 1,077 tested pathways are bolded. 
     
Trait Name chi2Pvalue empPvalue Pbon 
Sleep Duration KEGG_LONG_TERM_DEPRESSION 1.66E-06 1.00E-06 1.08E-03 
  REACTOME_NEURONAL_SYSTEM 6.80E-07 1.60E-06 1.72E-03 
  REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES 4.12E-06 5.20E-06 5.60E-03 
  KEGG_MAPK_SIGNALING_PATHWAY 2.36E-05 1.02E-04 1.10E-01 
  KEGG_GAP_JUNCTION 1.34E-04 1.30E-04 1.40E-01 
  REACTOME_HEMOSTASIS 4.13E-04 5.20E-04 5.60E-01 
  REACTOME_SIGNALING_BY_FGFR_IN_DISEASE 2.51E-04 5.57E-04 6.00E-01 
  REACTOME_SIGNALING_BY_FGFR 4.42E-04 7.10E-04 7.65E-01 
  REACTOME_MEIOTIC_SYNAPSIS 1.01E-03 9.00E-04 9.69E-01 
  REACTOME_PLC_BETA_MEDIATED_EVENTS 9.76E-04 1.06E-03 1.00 
Short Sleep REACTOME_DEVELOPMENTAL_BIOLOGY 3.17E-05 2.03E-05 2.19E-02 
  KEGG_LONG_TERM_DEPRESSION 1.29E-05 2.18E-05 2.35E-02 
  KEGG_MAPK_SIGNALING_PATHWAY 1.18E-05 2.42E-05 2.61E-02 
  REACTOME_SIGNALING_BY_FGFR_IN_DISEASE 3.74E-05 5.39E-05 5.81E-02 
  REACTOME_SIGNALING_BY_FGFR 3.84E-05 5.70E-05 6.14E-02 
  REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR 1.99E-04 2.26E-04 2.43E-01 
  REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS 1.32E-04 2.34E-04 2.52E-01 
  KEGG_NON_SMALL_CELL_LUNG_CANCER 1.35E-04 2.37E-04 2.55E-01 
  REACTOME_MAP_KINASE_ACTIVATION_IN_TLR_CASCADE 1.91E-04 2.61E-04 2.81E-01 
  REACTOME_FRS2_MEDIATED_CASCADE 3.15E-04 2.95E-04 3.18E-01 
Long Sleep KEGG_LONG_TERM_DEPRESSION 3.33E-04 2.94E-04 3.17E-01 
  REACTOME_TRAFFICKING_OF_GLUR2_CONTAINING_AMPA_RECEPTORS 6.57E-04 7.60E-04 8.19E-01 
  REACTOME_NEURONAL_SYSTEM 4.38E-04 7.80E-04 8.40E-01 
  BIOCARTA_P35ALZHEIMERS_PATHWAY 2.85E-03 8.90E-04 9.59E-01 
  REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES 7.69E-04 1.02E-03 1.00 
  BIOCARTA_BIOPEPTIDES_PATHWAY 5.24E-03 1.78E-03 1.00 
  KEGG_MAPK_SIGNALING_PATHWAY 2.48E-03 3.14E-03 1.00 
  REACTOME_CASPASE_MEDIATED_CLEAVAGE_OF_CYTOSKELETAL_PROTEINS 1.92E-02 3.35E-03 1.00 
  REACTOME_TRAFFICKING_OF_AMPA_RECEPTORS 7.39E-03 3.55E-03 1.00 
  
REACTOME_NEUROTRANSMITTER_RECEPTOR_BINDING_AND_DOWNSTREAM 




Supplementary Table 11. Enrichment analysis of synaptic sleep-need-index phosphoproteins (SNIPPs) human 
orthologs in sleep duration GWAS. 
          
  Sleep Duration Short Sleep Long Sleep 
Gene Symbol Chromosome Start End # SNPs P value # SNPs P value # SNPs P value 
SCN1A Chr 2 166845669 167005642 593 1.92E-09 593 4.40E-03 593 2.03E-04 
PDE4B Chr 1 66258192 66840262 1125 4.29E-09 1125 7.91E-08 1125 1.56E-01 
GRM5 Chr 11 88237743 88799113 1107 3.01E-06 1107 6.24E-05 1107 2.28E-01 
MAP2 Chr 2 210288770 210598834 604 9.75E-06 604 3.06E-03 604 4.26E-02 
MINK1 Chr 17 4736634 4801356 337 3.59E-05 337 6.62E-03 337 6.76E-03 
NAV1 Chr 1 201617449 201796102 459 8.70E-05 459 2.77E-06 459 4.74E-02 
PITPNM2 Chr 12 123468026 123635285 170 1.44E-04 170 5.07E-05 170 6.97E-01 
SHANK2 Chr 11 70313960 70935842 1234 5.55E-04 1234 5.35E-03 1234 2.99E-01 
RIMS1 Chr 6 72596405 73112845 1139 6.93E-04 1139 1.07E-01 1139 5.17E-01 
USP31 Chr 16 23072727 23160591 366 8.46E-04 366 1.10E-01 366 8.44E-02 
SCN2A Chr 2 166095911 166248820 491 1.05E-03 491 2.62E-02 491 6.84E-02 
ARFGAP2 Chr 11 47185848 47198676 137 1.20E-03 137 4.93E-03 137 1.15E-01 
LRRC7 Chr 1 70032867 70589171 1350 1.97E-03 1350 6.55E-02 1350 1.51E-01 
SRCIN1 Chr 17 36686258 36762183 325 1.99E-03 325 1.10E-01 325 1.41E-01 
ELFN2 Chr 22 37763999 37823505 367 2.01E-03 367 1.33E-02 367 6.12E-01 
SHANK3 Chr 22 51113069 51171640 230 3.06E-03 230 7.00E-01 230 9.92E-03 
PCLO Chr 7 82383320 82792197 992 3.30E-03 992 1.06E-01 992 7.01E-02 
ARHGEF2 Chr 1 155916629 155959864 138 3.45E-03 138 6.13E-03 138 8.52E-01 
AGAP2 Chr 12 58118075 58135944 131 1.05E-02 131 5.13E-02 131 2.10E-01 
DLGAP3 Chr 1 35331036 35370984 229 1.19E-02 229 4.34E-01 229 3.31E-01 
DLGAP2 Chr 8 1449531 1656642 997 1.53E-02 997 4.07E-03 997 3.27E-01 
GRIN2B Chr 12 13714409 14133022 1141 1.80E-02 1141 3.14E-01 1141 4.69E-01 
BAIAP2 Chr 17 79008946 79091232 599 1.85E-02 599 1.95E-01 599 9.55E-02 
SIPA1L1 Chr 14 71933901 72206120 292 2.17E-02 292 7.79E-02 292 3.72E-01 
SORBS2 Chr 4 186506597 186877870 1522 2.99E-02 1522 1.35E-01 1522 8.46E-01 
MARK4 Chr 19 45754515 45808541 326 3.20E-02 326 2.18E-01 326 1.64E-01 
TNIK Chr 3 170780291 171178197 993 3.25E-02 993 1.10E-02 993 9.55E-01 
DMXL2 Chr 15 51739920 51914967 351 3.64E-02 351 4.23E-03 351 1.17E-01 
ARHGAP39 Chr 8 145754562 145911194 116 4.05E-02 116 1.28E-01 116 4.83E-03 
MARK2 Chr 11 63606399 63678492 214 6.26E-02 214 7.56E-02 214 6.58E-01 
RAPGEF2 Chr 4 160188997 160281301 246 7.30E-02 246 2.16E-02 246 4.37E-01 
CAMK2B Chr 7 44256748 44365230 393 7.42E-02 393 1.58E-01 393 7.69E-01 
LPPR4 Chr 1 99729847 99775138 226 7.96E-02 226 9.62E-03 226 6.63E-01 
ANK3 Chr 10 61786055 62493284 1869 8.75E-02 1869 3.16E-02 1869 1.97E-02 
RIMS2 Chr 8 104512975 105266656 2182 1.11E-01 2182 5.58E-01 2182 5.16E-01 
DOCK7 Chr 1 62920396 63154039 330 1.41E-01 330 7.78E-01 330 6.56E-01 
BSN Chr 3 49591921 49708982 233 1.66E-01 233 4.36E-02 233 8.69E-01 
MARK1 Chr 1 220701567 220837799 255 1.69E-01 255 5.34E-02 255 6.04E-01 
MFF Chr 2 228189866 228222552 381 1.75E-01 381 1.37E-01 381 2.28E-01 
IQSEC1 Chr 3 12938541 13114617 656 1.75E-01 656 1.17E-02 656 1.33E-01 
CEP170 Chr 1 243287729 243418708 170 1.87E-01 170 1.29E-01 170 4.70E-02 
	 27 
ANKRD63 Chr 15 40573644 40574787 202 1.87E-01 202 8.03E-01 202 1.63E-01 
SYNPO Chr 5 149980641 150038792 153 2.04E-01 153 2.27E-01 153 4.48E-01 
C2CD4C Chr 19 405442 409170 258 2.18E-01 258 3.39E-01 258 7.47E-01 
TBC1D10B Chr 16 30368421 30381522 63 2.38E-01 63 2.79E-01 63 9.47E-01 
MAST1 Chr 19 12949258 12985766 121 2.64E-01 121 2.97E-01 121 1.39E-01 
TANC2 Chr 17 61086897 61505067 380 2.93E-01 380 4.00E-01 380 5.47E-02 
DNM1 Chr 9 130965662 131017527 213 0.31 213 0.052 213 0.55 
RAP1GAP2 Chr 17 2699731 2941035 902 3.21E-01 902 4.51E-01 902 5.62E-02 
BRSK1 Chr 19 55793439 55823903 236 3.25E-01 236 5.20E-01 236 7.89E-01 
ANKS1B Chr 12 99128568 100378432 2392 3.82E-01 2392 1.10E-01 2392 2.73E-01 
OSBPL6 Chr 2 179059207 179264160 515 4.05E-01 515 4.09E-01 515 4.51E-01 
CASKIN1 Chr 16 2227183 2246465 140 4.09E-01 140 8.71E-02 140 8.54E-01 
RAP1GAP Chr 1 21922707 21995856 456 4.27E-01 456 3.62E-01 456 5.02E-01 
ARHGAP21 Chr 10 24872537 25012597 378 4.61E-01 378 8.37E-01 378 5.92E-01 
CAMSAP1 Chr 9 138700332 138799005 332 0.47 332 0.59 332 0.29 
EXOC1 Chr 4 56719815 56771244 240 4.95E-01 240 7.01E-01 240 2.36E-01 
CADPS Chr 3 62384020 62861064 1363 5.58E-01 1363 4.51E-01 1363 4.51E-01 
ABI1 Chr 10 27035524 27150016 521 5.76E-01 521 4.51E-02 521 2.48E-01 
CACNA1E Chr 1 181452685 181775921 809 6.31E-01 809 6.03E-02 809 3.30E-01 
ARFGAP3 Chr 22 43192531 43253408 405 6.71E-01 405 7.45E-01 405 8.93E-01 
GPRIN1 Chr 5 176022802 176037131 211 6.96E-01 211 7.72E-01 211 2.14E-01 
CLASP2 Chr 3 33537738 33759705 368 7.29E-01 368 1.05E-01 368 3.16E-01 
ABL2 Chr 1 179068461 179198819 423 7.77E-01 423 6.50E-01 423 1.31E-01 
ILDR2 Chr 1 166882440 166944561 190 8.15E-01 190 7.75E-01 190 1.74E-01 
STK32C Chr 10 134020995 134146063 620 8.27E-01 620 5.48E-01 620 3.91E-01 
RAB11FIP5 Chr 2 73300509 73340146 299 9.23E-01 299 8.64E-01 299 5.86E-01 
CLASP1 Chr 2 122095351 122407052 543 9.23E-01 543 8.61E-01 543 6.03E-01 




Supplementary Table 12. Tissue enrichment analysis of gene expression in GTEx RNA-seq data using MAGMA. 
Significant tissue enrichments with P <9.43x10-04 for 53 tested tissues are bolded. 
          
  Sleep Duration Short Sleep Long Sleep 
Tissue Beta SE P Value Beta SE P Value Beta SE P Value 
Brain_Cerebellar_Hemisphere 0.0556 0.0089 2.21E-10 0.0388 0.0079 5.27E-07 0.0265 0.0071 9.81E-05 
Brain_Cerebellum 0.0559 0.0093 8.22E-10 0.0384 0.0082 1.61E-06 0.0261 0.0074 1.99E-04 
Brain_Frontal_Cortex_BA9 0.0593 0.0101 2.47E-09 0.0343 0.0090 6.91E-05 0.0208 0.0080 4.76E-03 
Brain_Cortex 0.0581 0.0104 1.27E-08 0.0334 0.0092 1.49E-04 0.0197 0.0082 8.15E-03 
Brain_Anterior_cingulate_cortex_BA24 0.0584 0.0108 2.84E-08 0.0326 0.0095 3.13E-04 0.0173 0.0085 2.10E-02 
Brain_Nucleus_accumbens_basal_ganglia 0.0573 0.0112 1.55E-07 0.0325 0.0099 5.17E-04 0.0070 0.0088 2.14E-01 
Brain_Caudate_basal_ganglia 0.0529 0.0118 3.62E-06 0.0310 0.0104 1.43E-03 0.0051 0.0092 2.89E-01 
Brain_Hippocampus 0.0526 0.0120 6.17E-06 0.0316 0.0106 1.44E-03 0.0113 0.0094 1.14E-01 
Brain_Hypothalamus 0.0525 0.0122 8.61E-06 0.0309 0.0107 2.00E-03 0.0055 0.0095 2.80E-01 
Brain_Putamen_basal_ganglia 0.0491 0.0119 1.77E-05 0.0282 0.0105 3.52E-03 0.0036 0.0093 3.48E-01 
Brain_Amygdala 0.0467 0.0120 4.72E-05 0.0270 0.0106 5.33E-03 0.0074 0.0094 2.16E-01 
Pituitary 0.0446 0.0135 5.03E-04 0.0252 0.0118 1.61E-02 0.0156 0.0102 6.39E-02 
Brain_Substantia_nigra 0.0348 0.0133 4.47E-03 0.0176 0.0117 6.59E-02 0.0040 0.0103 3.47E-01 
Testis 0.0150 0.0077 2.66E-02 0.0118 0.0069 4.27E-02 0.0035 0.0062 2.84E-01 
Brain_Spinal_cord_cervical_c.1 0.0155 0.0131 1.20E-01 0.0179 0.0115 5.99E-02 0.0032 0.0102 3.78E-01 
Cells_EBV.transformed_lymphocytes 0.0069 0.0073 1.71E-01 0.0008 0.0065 4.50E-01 0.0122 0.0059 1.93E-02 
Cells_Transformed_fibroblasts 0.0015 0.0108 4.47E-01 0.0026 0.0096 3.94E-01 0.0020 0.0085 4.07E-01 
Ovary -0.0021 0.0152 5.55E-01 0.0224 0.0131 4.33E-02 -0.0055 0.0114 6.85E-01 
Uterus -0.0136 0.0191 7.61E-01 -0.0013 0.0162 5.33E-01 -0.0041 0.0137 6.17E-01 
Colon_Sigmoid -0.0153 0.0209 7.68E-01 -0.0088 0.0176 6.91E-01 -0.0171 0.0148 8.75E-01 
Muscle_Skeletal -0.0076 0.0100 7.77E-01 -0.0117 0.0089 9.05E-01 0.0029 0.0080 3.61E-01 
Whole_Blood -0.0080 0.0080 8.40E-01 -0.0084 0.0072 8.79E-01 0.0013 0.0066 4.20E-01 
Cervix_Endocervix -0.0211 0.0208 8.44E-01 -0.0165 0.0175 8.27E-01 -0.0107 0.0146 7.68E-01 
Artery_Tibial -0.0236 0.0163 9.27E-01 -0.0138 0.0140 8.38E-01 -0.0189 0.0121 9.40E-01 
Nerve_Tibial -0.0266 0.0179 9.31E-01 -0.0057 0.0152 6.45E-01 -0.0076 0.0128 7.23E-01 
Esophagus_Muscularis -0.0314 0.0208 9.34E-01 -0.0252 0.0176 9.24E-01 -0.0098 0.0148 7.46E-01 
Esophagus_Gastroesophageal_Junction -0.0360 0.0221 9.49E-01 -0.0236 0.0186 8.98E-01 -0.0188 0.0155 8.88E-01 
Cervix_Ectocervix -0.0409 0.0233 9.61E-01 -0.0284 0.0195 9.28E-01 -0.0127 0.0161 7.85E-01 
Fallopian_Tube -0.0379 0.0216 9.61E-01 -0.0196 0.0181 8.61E-01 -0.0162 0.0150 8.60E-01 
Adrenal_Gland -0.0278 0.0154 9.65E-01 -0.0055 0.0133 6.59E-01 0.0009 0.0115 4.69E-01 
Thyroid -0.0321 0.0165 9.74E-01 -0.0215 0.0141 9.37E-01 -0.0062 0.0120 6.97E-01 
Skin_Not_Sun_Exposed_Suprapubic -0.0234 0.0119 9.76E-01 -0.0204 0.0104 9.75E-01 -0.0043 0.0092 6.82E-01 
Prostate -0.0430 0.0207 9.81E-01 -0.0389 0.0174 9.88E-01 -0.0142 0.0145 8.36E-01 
Skin_Sun_Exposed_Lower_leg -0.0248 0.0118 9.82E-01 -0.0218 0.0104 9.82E-01 -0.0068 0.0091 7.73E-01 
Heart_Atrial_Appendage -0.0334 0.0146 9.89E-01 -0.0200 0.0127 9.43E-01 -0.0209 0.0111 9.70E-01 
Heart_Left_Ventricle -0.0305 0.0131 9.90E-01 -0.0243 0.0115 9.83E-01 -0.0176 0.0102 9.58E-01 
	 29 
Bladder -0.0488 0.0208 9.91E-01 -0.0338 0.0175 9.73E-01 -0.0209 0.0146 9.24E-01 
Artery_Aorta -0.0404 0.0167 9.92E-01 -0.0206 0.0143 9.25E-01 -0.0164 0.0123 9.09E-01 
Colon_Transverse -0.0457 0.0174 9.96E-01 -0.0351 0.0148 9.91E-01 -0.0168 0.0126 9.08E-01 
Vagina -0.0521 0.0194 9.96E-01 -0.0334 0.0164 9.79E-01 -0.0201 0.0138 9.28E-01 
Kidney_Cortex -0.0394 0.0146 9.97E-01 -0.0224 0.0126 9.62E-01 -0.0180 0.0110 9.50E-01 
Minor_Salivary_Gland -0.0423 0.0157 9.97E-01 -0.0325 0.0135 9.92E-01 -0.0183 0.0116 9.42E-01 
Esophagus_Mucosa -0.0309 0.0114 9.97E-01 -0.0212 0.0100 9.83E-01 -0.0061 0.0089 7.54E-01 
Stomach -0.0549 0.0200 9.97E-01 -0.0363 0.0170 9.84E-01 -0.0361 0.0144 9.94E-01 
Spleen -0.0307 0.0109 9.98E-01 -0.0260 0.0096 9.97E-01 0.0050 0.0084 2.78E-01 
Pancreas -0.0414 0.0129 9.99E-01 -0.0220 0.0114 9.73E-01 -0.0144 0.0101 9.23E-01 
Small_Intestine_Terminal_Ileum -0.0424 0.0130 9.99E-01 -0.0272 0.0113 9.92E-01 -0.0056 0.0098 7.17E-01 
Liver -0.0301 0.0091 1.00 -0.0121 0.0081 9.32E-01 -0.0039 0.0073 7.03E-01 
Artery_Coronary -0.0701 0.0204 1.00 -0.0358 0.0172 9.82E-01 -0.0237 0.0144 9.49E-01 
Lung -0.0574 0.0154 1.00 -0.0307 0.0132 9.90E-01 -0.0155 0.0113 9.15E-01 
Adipose_Subcutaneous -0.0676 0.0179 1.00 -0.0349 0.0152 9.89E-01 -0.0178 0.0129 9.16E-01 
Adipose_Visceral_Omentum -0.0743 0.0185 1.00 -0.0288 0.0156 9.67E-01 -0.0219 0.0133 9.50E-01 
Breast_Mammary_Tissue -0.0896 0.0225 1.00 -0.0488 0.0187 9.95E-01 -0.0242 0.0155 9.41E-01 
          
MAGMA analysis conditioned on gene size, log gene size, gene density, log gene density, inverse minor allele 




Supplementary Table 13. Causal links of sleep duration (in minutes) with health outcomes using Mendelian 
Randomization. 
             
        Inverse Variance Weighted MR Egger Weighted Median 
Outcome Study PMID SNPs 
Beta/ 
log OR SE P value 
Beta/ 
log OR SE P value 
Beta/ 
log OR SE P value 
Insomnia, log OR UK Biobank  N/A 73 -0.004 0.000 2.87E-24 -0.006 0.001 8.70E-06 -0.004 0.000 1.32E-26 
Schizophrenia, log OR PGC 25056061 67 0.0088 0.003 3.70E-03 0.015 0.011 0.20 0.008 0.003 3.95E-03 
Bipolar disorder, log OR PGC 21926972 53 0.006 0.004 1.52E-01 0.0002 0.018 0.99 0.001 0.006 8.90E-01 
PGC cross-disorder traits, log OR PGC 23453885 48 0.003 0.002 2.11E-01 0.001 0.010 0.95 0.001 0.003 8.62E-01 
Age at menarche, years  ReproGen 25231870 53 0.003 0.001 3.74E-02 0.0001 0.006 0.98 0.002 0.002 2.82E-01 
Body mass index, kg/m2 GIANT 25673413 53 0.001 0.001 0.42 0.001 0.003 0.72 0.001 0.001 0.41 
Type 2 diabetes, log OR DIAGRAM 24509480 52 0.001 0.003 0.67 -0.009 0.010 0.40 0.000 0.004 1.00 
             
Beta is the estimated effect of change on outcome in units indicated (continuous) or log odds ratio for case/control traits 
using the SNPs associated with sleep duration with available proxies in each study (number of SNPs used indicated in 
the SNPs column) using effect estimates for sleep duration in minutes (Supplementary Data 1). Three Mendelian 
Randomization methods were used. Each outcome was obtained from publicly available GWAS summary data.  The 





Supplementary Table 14. Bidirectional causal links of sleep duration (in minutes) with schizophrenia (log odds ratio) 
using two-sample Mendelian Randomization. 
            
      Inverse Variance Weighted MR Egger Weighted Median 
Exposure Outcome SNPs Beta SE P value Beta SE P value Beta SE P value 
Sleep duration  
(UK Biobank -  
baseline adjustment) Schizophrenia (PGC) 67 0.009 0.003 3.70E-03 0.015 0.011 0.20 0.008 0.003 3.95E-03 
Sleep duration  
(UK Biobank -  
BMI adjustment) Schizophrenia (PGC) 65 0.009 0.003 5.18E-03 0.016 0.012 0.18 0.008 0.003 5.12E-03 
Sleep duration  
(UK Biobank -  
insomnia adjustment) Schizophrenia (PGC) 43 0.009 0.003 8.48E-03 0.012 0.012 0.34 0.009 0.003 1.05E-02 
Sleep duration  
(UK Biobank -  
lifestyle adjustment) Schizophrenia (PGC) 48 0.008 0.003 2.03E-02 0.011 0.012 0.37 0.008 0.003 1.46E-02 
Sleep duration  
(UK Biobank -  
only meta-analysis GWAS loci) Schizophrenia (PGC) 48 0.006 0.003 6.16E-02 0.0157 0.012 0.20 0.008 0.003 8.14E-03 
                Exposure         Outcome SNPs Log OR SE P value Log OR SE P value Log OR SE P value 
Schizophrenia (PGC) 
Sleep duration  
(UK Biobank -  
baseline adjustment) 69 0.025 0.007 6.05E-04 0.026 0.027 0.35 0.026 0.006 3.36E-05 
	
Abbreviations: MR =Mendlian randomization; OR =odds ratio	
